Risk factor
Resilient to price shocks
Profitability factor
Weak growth
About
KPC Pharmaceuticals, Inc. operates as a pharmaceutical enterprise, with its operations spanning drug research and development, manufacturing, marketing, and wholesale distribution. The company serves both domestic markets within the People's Republic of China and international clientele. Its portfolio prominently features botanical drugs, including artemether, panax notoginseng, and gastrodine series medications. These, along with various Chinese and ethnic remedies—marketed under brand names such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco—are deployed in the treatment of conditions affecting the cardiovascular and cerebrovascular systems, neurological disorders, and malaria. Beyond its herbal focus, KPC Pharmaceuticals supplies a broad range of healthcare products. These include Dai ethnic preparations, antibiotics, raw chemical materials, prepared chemical pharmaceuticals, traditional Chinese medicinal ingredients, biologicals, biochemical agents, and nutritional supplements. Specific offerings encompass Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, Ribavirin spray, glycyrrhizic acid, and the long-acting hypoglycemic GLP-1. Additionally, the company distributes artemisinin-based antimalarials, various generic medications, and medical devices. Established in 1951, the firm was initially known as Kunming Pharmaceutical Corporation before adopting its current name, KPC Pharmaceuticals, Inc., in April 2015. Its corporate headquarters are located in Kunming, situated in the People's Republic of China.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair